

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/064075 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) A61P 29/00 (2006.01)
C07D 403/12 (2006.01) A61P 37/00 (2006.01)
C07D 495/04 (2006.01) A61K 31/429 (2006.01)
C07D 513/04 (2006.01)

(21) International Application Number:

PCT/EP2021/076715

(22) International Filing Date:

28 September 2021 (28.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20306111.4 28 September 2020 (28.09.2020) EP

(71) Applicants: **ERMIMUM THERAPEUTICS** [FR/FR];
16 boulevard Saint Germain, 75005 Paris (FR).
UNIVERSITÉ DE PARIS [FR/FR]; 85, boulevard Saint-
Germain, 75006 Paris (FR). **CENTRE NATIONAL DE
LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, Rue
Michel-Ange, 75016 Paris Cedex 16 (FR).

(72) Inventors: **HERBEUVAL, Jean-Philippe**; 16 rue Gaston
de Caillavet, 75015 Paris (FR). **BARRÉ, Anaïs**; 2 rue de
Gunsbach, 67400 Illkirch Graffenstaden (FR). **CASSOU,
Julie**; 10 impasse du vieux-Rhin, 67114 Eschau (FR).
MAYER, Stanislas; 10 rue des jardins, 67114 Eschau (FR).
BAZZINI, Patrick; 9 rue de la Faisanderie, 67100 Stras-
bourg (FR).

(74) Agent: **OSWIN RIDDERBUSCH, VOSSIUS & PART-
NER**; Patentanwälte Rechtsanwälte mbB, Siebertstrasse 3,
81675 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,


NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS



(57) Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.

WO 2022/064075 A1